Barclays Keeps Their Hold Rating on Ironwood Pharma


In a report released yesterday, Geoff Meacham from Barclays maintained a Hold rating on Ironwood Pharma (NASDAQ: IRWD), with a price target of $20. The company’s shares opened today at $18.79, close to its 52-week high of $19.94.

According to TipRanks.com, Meacham is a 3-star analyst with an average return of 3.5% and a 51.1% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, United Therapeutics, and Johnson & Johnson.

Ironwood Pharma has an analyst consensus of Strong Buy, with a price target consensus of $21.40.

See today’s analyst top recommended stocks >>

Based on Ironwood Pharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $69.16 million and GAAP net loss of $43.14 million. In comparison, last year the company earned revenue of $52.17 million and had a GAAP net loss of $52.5 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which discovers, develops and intends to commercialize differentiated medicines that improve patient’s lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts